A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

FDA Provides EUA for COVID-19 Treatment


On November 9, the United States Food and Drug Administration issued an emergency use authorization (EUA) to bamlanivimab for the treatment of mild-to-moderate COVID-19. The monoclonal antibody therapy is authorized for COVID-19 patients who are age 12 and older, who weigh at least 88 pounds, and who are at high risk of severe COVID-19 and/or hospitalization. This includes patients who are older than 65 and those with preexisting systemic health problems. Clinical trials demonstrated that bamlanivimab reduced COVID-19-related hospitalization or emergency department visits in patients at high risk for disease progression compared to a placebo. Additional research is needed, however, to fully establish safety and efficacy. Read more here.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy